Literature DB >> 11891851

Orphan nuclear receptor binding site in the human inducible nitric oxide synthase promoter mediates responsiveness to steroid and xenobiotic ligands.

Andrea Toell1, Klaus-Dietrich Kröncke, Hartmut Kleinert, Carsten Carlberg.   

Abstract

Constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are members of the nuclear receptor superfamily that regulate target gene transcription in a ligand-dependent manner. CAR and PXR have a rather broad, overlapping set of ligands that range from natural steroids to xenobiotics and also recognize similar DNA binding sites, referred to as response elements (REs), primarily in promoter regions of cytochrome P450 (CYP) genes. In this study, a CAR and PXR RE, composed of a direct repeat of two GGTTCA motifs in a distance of 4 nucleotides (DR4), was identified in the promoter of the human inducible nitric oxide (NO) synthase (iNOS) gene, which is the first nuclear receptor binding site reported for this promoter. In a heterologous promoter context, the DR4-type sequence also acts as a functional RE for the nuclear receptors for 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25OH2D3) and 3,5,3'-triiodothyronine (T3), VDR and T3R. However, in a direct competition of CAR, PXR, VDR, and T3R, the PXR-retinoid X receptor (RXR) complex appears to be the dominant regulator on the iNOS DR4-type RE. In the natural iNOS promoter context, the DR4-type RE specifically mediates downregulation of promoter activity by the testosterone metabolite androstanol through CAR-RXR heterodimers and upregulation by the xenobiotic drug clotrimazole through PXR-RXR heterodimers. These results were confirmed on the level of mRNA expression. Since an iNOS-induced production of NO is known to influence inflammation and apoptosis, a CAR- and PXR-regulated iNOS activity may explain a modulatory effect of steroids and xenobiotics on these cellular processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891851

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  20 in total

1.  Effect of rifampin on production of inflammatory mediators in HepG2 liver epithelial cells.

Authors:  Yael Yuhas; Eva Berent; Shai Ashkenazi
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 2.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

Review 3.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

4.  Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands.

Authors:  Ann M Dring; Linnea E Anderson; Saima Qamar; Matthew A Stoner
Journal:  Chem Biol Interact       Date:  2010-10-20       Impact factor: 5.192

5.  PPARγ and NF-κB regulate the gene promoter activity of their shared repressor, TNIP1.

Authors:  Igor Gurevich; Carmen Zhang; Priscilla C Encarnacao; Charles P Struzynski; Sarah E Livings; Brian J Aneskievich
Journal:  Biochim Biophys Acta       Date:  2011-10-07

6.  Molecular dynamics simulations of the human CAR ligand-binding domain: deciphering the molecular basis for constitutive activity.

Authors:  Björn Windshügel; Johanna Jyrkkärinne; Antti Poso; Paavo Honkakoski; Wolfgang Sippl
Journal:  J Mol Model       Date:  2004-12-23       Impact factor: 1.810

Review 7.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

Review 8.  Small-molecule modulators of the constitutive androstane receptor.

Authors:  Milu T Cherian; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05-15       Impact factor: 4.481

9.  Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Authors:  Ying Ou; Yang Xu; Lia Gore; R Donald Harvey; Alain Mita; Kyriakos P Papadopoulos; Zhengping Wang; Richard E Cutler; Dawn E Pinchasik; Apostolia M Tsimberidou
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

10.  Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells.

Authors:  Suman Verma; Michelle M Tabb; Bruce Blumberg
Journal:  BMC Cancer       Date:  2009-01-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.